# A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

> **NCT01472848** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Obesity

## Interventions

- **DRUG:** PF 05212389 or placebo
- **DRUG:** PF 05212389 or placebo
- **DRUG:** PF 05212389 or placebo
- **DRUG:** PF 05212389 or placebo
- **DRUG:** PF 05212389 or placebo
- **DRUG:** PF 05212389 or placebo

## Key facts

- **NCT ID:** NCT01472848
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472848, "A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01472848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*